GlassScriptPhysician profile
Kelly J Murray
NPI 1821388836
$17,961.41
in general payments reported to CMS, 2019-2025
27 companies · $6,699 in 2025
The $6,699 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,981 · 2022: $1,137 · 2023: $1,571 · 2024: $6,574 · 2025: $6,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,344 · Food and Beverage: $5,539 · Travel and Lodging: $2,399 · Education: $378 · Consulting Fee: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,343.75 |
| Food and Beverage | $5,538.84 |
| Travel and Lodging | $2,399.09 |
| Education | $378.04 |
| Consulting Fee | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,259.69 | 2021-2025 | |
| Janssen Biotech, INC. | $1,029.18 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $814.14 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $808.97 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $655.46 | 2022-2024 | Sotyktu |
| Ucb, INC. | $577.85 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $435.79 | 2022-2025 | Opzelura |
| Genzyme Corporation | $430.97 | 2021-2025 | |
| Lilly USA, LLC | $383.53 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $250.71 | 2021-2025 | |
| Leo Pharma INC. | $249.16 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $230.09 | 2021-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $149.98 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $128.02 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $101.86 | 2023-2025 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $99.97 | 2021-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $66.13 | 2021-2022 | |
| Organon LLC | $58.48 | 2025 | Vtama |
| Dermavant Sciences, INC. | $58.23 | 2023-2024 | Vtama |
| Abbott Laboratories | $45.88 | 2021 | |
| Verrica Pharmaceuticals INC. | $34.55 | 2024 | Ycanth |
| Olympus America INC. | $20.64 | 2022 | |
| Botanix Sb INC | $16.91 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.32 | 2023 | Siliq, Targretin |
| Dermira, INC. | $13.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Almirall LLC | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.